Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Nature Microbiology - Tập 5 Số 12 - Trang 1598-1607
Jeffrey Seow1, Carl Graham1, Blair Merrick2, Sam Acors1, Suzanne Pickering1, Kathryn J. A. Steel3, Oliver Hemmings4, Aoife M. O’Byrne3, Neophytos Kouphou1, Rui Pedro Galão1, Gilberto Betancor1, Harry Wilson1, Adrian W. Signell1, Helena Winstone1, Claire Kerridge1, Isabella Huettner1, Jose M. Jiménez-Guardeño1, María José Lista1, Nigel Temperton5, Luke B. Snell2, Karen Bisnauthsing2, Amelia Moore6, Adrian Green6, Lauren Martinez6, Brielle Stokes6, Johanna Honey6, Alba Izquierdo-Barras6, Gill Arbane7, Amita Patel2, Mark Tan Kia Ik2, Lorcan O’Connell2, Geraldine O’Hara2, Eithne MacMahon2, Sam Douthwaite2, Gaia Nebbia2, Rahul Batra2, Rocío T. Martínez-Nuñez1, Manu Shankar‐Hari7, Jonathan D. Edgeworth2, Stuart J. D. Neil1, Michael H. Malim1, Katie J. Doores1
1Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
2Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK
3Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London, London, UK
4Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK
5Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, UK
6Guy's and St Thomas' R&D Department, Guy's and St Thomas' NHS Foundation Trust, London, UK
7Department of Intensive Care Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Tóm tắt

Từ khóa


Tài liệu tham khảo

Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. https://doi.org/10.1038/s41591-020-0913-5(2020).

Gorse, G. J., Donovan, M. M. & Patel, G. B. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. J. Med. Virol. 92, 512–517 (2020).

Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845–848 (2020).

Luchsinger, L. L. et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID19 patients. J. Clin. Microbiol. https://doi.org/10.1128/JCM.02005-20 (2020).

Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg. Infect. Dis. 26, 1478–1488 (2020).

Pickering, S. et al. Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog. 16, e1008817 (2020).

Prevost, J. et al. Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike. Cell Rep. Med. 1, 100126 (2020).

Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science https://doi.org/10.1126/science.abc5902 (2020).

Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell https://doi.org/10.1016/j.cell.2020.05.025 (2020).

Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science https://doi.org/10.1126/science.abc7520 (2020).

Shi, R. et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2381-y (2020).

Crawford, K. H. D. et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. J. Infect. Dis. https://doi.org/10.1093/infdis/jiaa618 (2020).

Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200–1204 (2020).

Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435–446 (1990).

Kellam, P. & Barclay, W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J. Gen. Virol. https://doi.org/10.1099/jgv.0.001439 (2020).

Mo, H. et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology 11, 49–53 (2006).

Moore, J. P. & Klasse, P. J. SARS-CoV-2 vaccines: ‘Warp Speed’ needs mind melds not warped minds. J. Virol. https://doi.org/10.1128/JVI.01083-20 (2020).

Edridge, A. W. D. et al. Seasonal coronavirus protective immunity is short-lasting. Nat. Med. https://doi.org/10.1038/s41591-020-1083-1 (2020).

Cao, W. C., Liu, W., Zhang, P. H., Zhang, F. & Richardus, J. H. Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med. 357, 1162–1163 (2007).

Lee, W. T. et al. Neutralizing antibody responses in COVID-19 convalescent sera. Preprint at medRxiv https://doi.org/10.1101/2020.07.10.20150557 (2020).

Wu, F. et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern. Med. https://doi.org/10.1001/jamainternmed.2020.4616 (2020).

Wang, M. et al. Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China. PLoS ONE 6, e16809 (2011).

Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903–1915 (2007).

Choe, P. G. et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg. Infect. Dis. 23, 1079–1084 (2017).

Grehan, K., Ferrara, F. & Temperton, N. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX 2, 379–384 (2015).

Thompson, C. et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors—a pilot study of the value of serology to determine population exposure. Preprint at medRxiv https://doi.org/10.1101/2020.04.13.20060467 (2020).

Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Preprint at medRxiv https://doi.org/10.1101/2020.06.10.20126532 (2020).

Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, https://doi.org/10.1084/jem.20201181 (2020).

Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature https://doi.org/10.1038/s41586-020-2380-z (2020).

Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. https://doi.org/10.1038/s41591-020-1038-6 (2020).

Muecksch, F. et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. Preprint at medRxiv https://doi.org/10.1101/2020.08.05.20169128 (2020).

Lee, N. et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J. Clin. Virol. 35, 179–184 (2006).

Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat. Rev. Immunol. 20, 339–341 (2020).

Wajnberg, A. et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. Preprint at medRxiv https://doi.org/10.1101/2020.07.14.20151126 (2020).

Iyer, A. S. et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci. Immunol. 5, eabe0367 (2020).

Beaudoin-Bussières, G. et al. Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. mBio 11, e02590–20 (2020).

Isho, B. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci. Immunol. 5, eabe5511 (2020).

Wu, J. et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Preprint at medRxiv https://doi.org/10.1101/2020.07.21.20159178 (2020).

Wang, K. et al. Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1143 (2020).

Seydoux, E. et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity https://doi.org/10.1016/j.immuni.2020.06.001 (2020).

Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Preprint at medRxiv https://doi.org/10.1101/2020.08.11.20171843 (2020).

Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature https://doi.org/10.1038/s41586-020-2456-9 (2020).

Petersen, eK. M. et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect. 20, e238–e244 (2020).

Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science https://doi.org/10.1126/science.abc4776 (2020).

Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science https://doi.org/10.1126/science.abc5343 (2020).

Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2022483 (2020).

Keech, C. et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2026920 (2020).

Gao, Q. et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science https://doi.org/10.1126/science.abc1932 (2020).

Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).

van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature https://doi.org/10.1038/s41586-020-2608-y (2020).

Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science https://doi.org/10.1126/science.abc6284 (2020).

Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2024671 (2020).

Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell Press 183, 158–168 (2020).

Carter, M. J. et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat. Med. https://doi.org/10.1038/s41591-020-1054-6 (2020).

Thông tin
Thông tin xuất bản

Nature Microbiology

Tập 5 Số 12

1598-1607

Thông tin tác giả